M2 PRESSWIRE-February 9, 2011-OTC Tip Reporter: Unigene Laboratories, Inc. (OTCBB: UGNE), Li3 Energy, Inc. (OTCBB: LIEG), IntelGenx Corp. (OTCBB: IGXT): Sign-Up for our FREE Stock Picks TODAY!(C)1994-2011 M2 COMMUNICATIONS
RDATE:09022011
www.OTCtipReporter.com Unigene Laboratories, Inc. (OTCBB: UGNE), Li3 Energy, Inc. (OTCBB: LIEG), IntelGenx Corp. (OTCBB: IGXT)
Sign-Up for our FREE Stock Picks AND OUR AWARD WINNING NEWSLETTER at
www.OTCtipReporter.com
_______________________________________________________________________________
For a FREE Report Visit: www.OTCtipReporter.com
www.OTCtipReporter.com is a premier source for Top penny stocks research.
Unigene to Present at the 13th Annual BIO CEO and Investor Conference on February 14, 2011
BOONTON, N.J. -- 2/7/2011-- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that Ashleigh Palmer, President and CEO will be presenting a corporate overview at the 13th Annual BIO CEO & Investor Conference. Mr. Palmer's presentation is scheduled to begin at 9:30 a.m. Eastern time on Monday, February 14, 2011.
Individuals can listen to a live webcast of the presentation by logging on to the Investors and Media section of the Unigene web site, http://www.unigene.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence(TM) platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigene's technologies have extensive clinical and partner validation. The Company's first product to market, Fortical(r), a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis. Other validating relationships include an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.
For more information about Unigene, please visit http://www.unigene.com. For information about Fortical, please visit http://www.fortical.com.
_______________________________________________________________________________
For a FREE Report Visit: www.OTCtipReporter.com
www.OTCtipReporter.com is a premier source for Top penny stocks research.
Li3 Energy, Inc. Announces the Engagement of SignumBOX in Order to Complete a Project Evaluation Report
LIMA, Peru, Feb. 7, 2011 -- Li3 Energy, Inc. (OTC Bulletin Board: LIEG) ("Li3 Energy" or the "Company") is pleased to announce it has engaged SignumBOX in order to complete a project evaluation report for the Maricunga lithium project in Chile. The purpose of the report is to have an independent analysis on the Maricunga project that the Company has signed a letter of intent to acquire.
SignumBOX has previously issued several reports regarding the use of lithium in batteries and vehicles and its prospects and trends. SignumBOX is a Chilean based company with extensive experience in the lithium industry and has developed the SignumBOX index ranking more than 70 lithium projects using a quantitative and objective method.
The report to be generated by SigumBOX will be completed over five weeks and will include a review of Maricunga's geological characteristics and a comparison between the Maricunga salar and other salars that are currently being developed by other companies. Further important aspects that will be covered in this report are: i) review of the Li3 Energy position in terms of its ability to develop the project; ii) development of a position analysis of Li3's Maricunga project with other lithium brine projects; iii) identification of the principal strengths and weaknesses of the Maricunga project; and iv) Maricunga's potential synergies with Li3's Alfredo project and its strategy to become a diversified, low-cost minerals producer Luis Saenz, Li3 Energy CEO, commented: "We are pleased to have a firm with the prestige of SignumBOX reviewing our project. Independent analysis is always very important at this critical stage of development, and we are confident it will demonstrate the robust nature of an asset we believe to have world-class potential and help us in taking the correct steps going forward."
Closing of the Maricunga acquisition is subject to satisfactory completion of due diligence, financing of the cash purchase price and work commitment by Li3, and other customary conditions.
About Li3 Energy, Inc.
Li3 Energy, Inc. is an early stage, U.S. public company currently pursuing a business strategy in the lithium mining and energy sector in the Americas, with an initial focus on identifying and acquiring opportunities in Peru, Argentina and Chile and the United States. Li3 Energy aims to acquire a significant portfolio of lithium brine deposits in the Americas for the purpose of development and production in order to meet growing market demand and to support the clean energy and green energy initiatives being implemented globally.
www.li3energy.com
Forward-Looking Statements
All statements other than statements of historical facts included in this news release including, without limitation, statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "potential," "target," "goal," "plans," "objective," "should" or similar expressions or variations on such expressions are forward-looking statements. The Company can give no assurances that the assumptions upon which the forward-looking statements are based will prove to be correct. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. There are a number of risks, uncertainties and other important factors that could cause the Company's actual results to differ materially from the forward-looking statements, including, but not limited to, the Company's ability to identify appropriate corporate acquisition and/or joint venture opportunities in the lithium mining sector and to establish the technical and managerial infrastructure, and to raise the required capital, to take advantage of, and successfully participate in such opportunities; future economic conditions; political stability; and lithium prices. For further information about certain risks faced by the Company, see "Risk Factors" in Part I, Item 1A of Amendment No. 1 to our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on November 5, 2010.
The Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
_______________________________________________________________________________
For a FREE Report Visit: www.OTCtipReporter.com
www.OTCtipReporter.com is a premier source for Top penny stocks research.
IntelGenx Achieves Positive Bioequivalence Results for a Leading Branded Anti-Psychotic Using VersaFilm Oral Thin Film Technology
F
SAINT LAURENT, QUEBEC - Feb. 7, 2011 -- IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") today announced the completion of a pilot study that indicates that IntelGenx has successfully developed a novel oral film, INT0022, that is bioequivalent to a leading branded anti-psychotic. INT0022 has been developed using IntelGenx' proprietary immediate release "VersaFilm" drug delivery technology. According to IMS Health, the global anti-psychotic market was worth $22.5 billion in 2008.
IntelGenx' President and CEO Dr. Horst Zerbe commented, "We now have successfully demonstrated bioequivalence in humans with three different thin film products, giving IntelGenx what we believe is one of the deepest thin film pipelines in the pharmaceutical industry."
This was a randomized, two-period, two-way crossover study in healthy male subjects. The study was designed to determine whether INT0022 is bioequivalent to a leading anti-psychotic product as measured by industry standard pharmacokinetic measures, peak plasma concentration (Cmax) and area under the curve (AUC). The study results indicate that INT0022 falls within the range of bioequivalency for both Cmax and AUC and allow IntelGenx to advance the product to the pivotal bioequivalency study.
"Oral thin films could offer some unique advantages over conventional methods of medication, especially in patients with anti-psychotic behavioural symptoms where patient compliance is an issue," added Dr. Zerbe. "Furthermore, our thin films are engineered to reduce drug exposure in the gastrointestinal tract, which could be a substantial benefit in minimizing certain GI related side effects that are frequently associated with anti-psychotic medicines. We will be exploring this and other potential benefits in our upcoming pivotal study."
Following the successful completion of the INT0022 pilot study, the Company now plans to commence scale-up and manufacturing of the pivotal batches required to support a pivotal clinical study and a future regulatory 505(b)(2) filing.
About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of pain, hypertension, erectile dysfunction and depressive disorders. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2009, filed with the United States Securities a Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
_______________________________________________________________________________
For a FREE Report Visit: www.OTCtipReporter.com
To feature your publicly traded company in our alerts, email us at: office@OTCtipReporter.com
Let OTC Tip Reporter help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at office@OTCtipReporter.com
About OTCtipReporter.com
www.OTCtipReporter.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
www.OTCtipReporter.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity. To subscribe to this free service, visit the OTCtipReporter Stock Report home page at http://www.OTCtipReporter.com and Sign up Free For "Daily Stock Alerts".
Join us at http://www.OTCtipReporter.com for a complimentary subscription to the most exciting online financial newsletter.
To feature your publicly traded company in our alerts, email us at: office@OTCtipReporter.com
Disclaimer: Verify all claims and do your own due diligence. OTCtipReporter.com profiles are not a solicitation or recommendation to buy, sell or hold securities. OTCtipReporter.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. OTCtipReporter.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), OTCtipReporter.com is owned and operated by OTCtipReporter.com. Neither OTCtipReporter.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since OTCtipReporter.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in OTCtipReporter.com statements and opinions and such statements and opinions cannot be considered independent. OTCtipReporter.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. OTCtipReporter.com services are often paid for using free-trading shares. OTCtipReporter.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: http://www.otctipreporter.com/disclaimer.htm
To feature your publicly traded company in our alerts, email us at: office@OTCtipReporter.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).
Комментариев нет:
Отправить комментарий